The therapeutic potential of synthetic human atrial natriuretic peptide in nephrotic syndrome: a randomized controlled trial

Figures & data

Table 1 Comparison of clinical characteristics of synthetic human atrial natriuretic peptide treatment (hANP) and conventional treatment (CON) groups at baseline

	hANP (n = 7)	CON (n = 5)	P values
Gender (female:male)	3:4	2:3
Age (year)	59.4 ± 5.3	67.0 ± 4.0	ns
Systolic BP (mmHg)	147.9 ± 12.0	147.0 ± 12.6	ns
Diastolic BP (mmHg)	78.0 ± 5.7	82.0 ± 6.1	ns
Heart rate (beats/min)	85.1 ± 6.3	74.8 ± 3.9	ns
Serum total protein (g/L)	49.0 ± 4.0	53.0 ± 4.0	ns
Serum albumin (g/L)	23 ± 2.0	23.0 ± 3.0	ns
Urinary protein excretion (g/day)	6.3 ± 1.9	5.9 ± 1.3	ns
Underlying diseases
Diabetic nephropathy	n = 6	n = 2
Primary glomerulonephritis	n = 1	n = 3

Abbreviations: hANP, synthetic human atrial natriuretic peptide treatment; CON, conventional treatment; BP, blood pressure; ns, not significant.

Figure 1 CONSORT (Consolidated Standards of Reporting Trials) diagram for the current study.

Table 2 Clinical parameters at baseline and follow-up in synthetic human atrial natriuretic peptide treatment (hANP) and conventional treatment (CON) groups

	hANP			CON
	Baseline	2 weeks	P	Baseline	2 weeks	P
Systolic BP (mmHg)	147.9 ± 12.0	131.7 ± 5.9	ns	147.0 ± 12.6	131.4 ± 11.4	ns
Diastolic BP (mmHg)	78.0 ± 5.7	71.9 ± 7.9	ns	82.0 ± 6.1	75.4 ± 11.5	ns
Heart rate (beats/min)	85.1 ± 6.3	77.6 ± 3.4	ns	74.8 ± 3.9	78.5 ± 3.1	ns
Body weight (kg)	61.0 ± 3.5	58.6 ± 3.8	ns	65.2 ± 18.7	61.6 ± 18.7	ns
Serum sodium (mmol/L)	136.0 ± 2.0	139.0 ± 1.0	ns	141.0 ± 2.0	142.0 ± 1.0	ns
Serum potassium (mmol/L)	4.4 ± 0.1	4.37 ± 0.3	ns	4.50 ± 0.2	3.92 ± 0.2	ns
Serum total protein (g/L)	49.0 ± 2.0	51.0 ± 8.0	ns	53.0 ± 4.0	52.0 ± 11.0	ns
Serum albumin (g/L)	23.0 ± 2.0	25.0 ± 2.0	ns	23.0 ± 3.0	26.0 ± 3.0	ns
Serum creatinine (μmol/L)	176.8 ± 79.6	185.6 ± 88.4	P < 0.05	221.0 ± 88.4	238.7 ± 114.9	P < 0.05
Serum uric acid (μmol/dL)	399.0 ± 107.0	387.0 ± 83.0	ns	494.0 ± 48.0	595.0 ± 48.0	ns
Serum urea nitrogen (mmol/L)	15.5 ± 21.8	9.1 ± 7.2	ns	9.9 ± 5.7	13.3 ± 2.9	ns
Urinary protein excretion (g/day)	6.8 ± 5.4	5.6 ± 3.2	ns	5.9 ± 1.3	6.6 ± 2.3	ns

Abbreviations: hANP, synthetic human atrial natriuretic peptide treatment; CON, conventional treatment; BP, blood pressure; ns, not significant.

Figure 2 Comparison of changes of clinical parameters and total dose of furosemide and albumin in synthetic human atrial natriuretic peptide treatment (hANP) and conventional treatment (CON) groups. Note: *P < 0.05.